Classical anti-oxidants (scavengers) versus biological anti-oxidants (suppressors of ROS generation): A novel way to explain the anti-oxidant paradox

Metabolic Syndrome and Related Disorders

Volumn 2, Issue 3, 2004, Pages 155-159

  Dandona, Paresh ^a,b   Dhindsa, Sandeep ^a   Aljada, Ahmad ^a   Chaudhuri, Ajay ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b Diabetes Endocrinology Center of Western New York   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; ISOPROSTANE; LOSARTAN; MALONALDEHYDE; PIOGLITAZONE; QUINAPRIL; RAMIPRIL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RETINOL; SCAVENGER; SIMVASTATIN; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TROGLITAZONE; VALSARTAN;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIETARY INTAKE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPERLIPIDEMIA; LIPID OXIDATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; VITAMIN SUPPLEMENTATION;

EID: 15944365189     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2004.2.155     Document Type: Review

References (41)

1. Palinski W, Rosenfeld ME, Yla-Herttuala S, et al. Low-density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A 1989;86: 1372-1376.
2. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-924.
3. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342: 154-160.
4. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in post-menopausal women: a randomized controlled trial. JAMA 2002;288:2432-2440.
5. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000;356:1213-1218.
6. Fang JC, Kinlay S, Beltrame J, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 2002;359: 1108-1113.
7. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-1592.
8. Dandona P, Karne R, Ghanim H, et al. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000;101:122-124.
9. Magsino CH, Jr., Hamouda W, Bapna V, et al. Nadolol inhibits reactive oxygen species generation by leukocytes and linoleic acid oxidation. Am J Cardiol 2000;86:443-448.
10. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-720.
11. Ruiz-Ortega M, Lorenzo O, Ruperez M, et al. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000; 86:1266-1272.
12. Pueyo ME, Gonzalez W, Nicoletti A, et al. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000;20:645-651.
13. Zahradka P, Werner JP, Buhay S, et al. NF-kappaB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. J Mol Cell Cardiol 2002; 34:1609-1621.
14. Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003;88:4496-4501.
15. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003;42:905-910.
16. Tsutamoto T, Wada A, Maeda K, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 2000;35:714-721.
17. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-1010.
18. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
19. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-259.
20. Khan BV, Sola S, Lauten WB, et al. Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care 2004;27:1712-1715.
21. Koh KK, Son JW, Ahn JY, et al. Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension 2004;44:180-185.
22. Koh KK, Son JW, Ahn JY, et al. Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study. Atherosclerosis 2004;177:147-153.
23. Wassmann S, Ribaudo N, Faul A, et al. Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels <130 mg /dl. Am J Cardiol 2004;93:84-88.
24. Koh KK, Son JW, Ahn JY, et al. Vascular effects of diet and statin in hypercholesterolemic patients. Int J Cardiol 2004;95:185-191.
25. Harangi M, Seres I, Varga Z, et al. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur J Clin Pharmacol 2004;60:685-691.
26. Barnes PJ, Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
27. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001;86:3257-3265.
28. Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001;86: 1306-1312.
29. Dandona P, Aljada A, Bandyopadhyay A: Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004;25:4-7.
30. Dandona P, Thusu K, Cook S, et al. Oxidative damage to DNA in diabetes mellitus. Lancet 1996;347: 444-445.
31. Dandona P, Weinstock R, Thusu K, et al. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998;83:2907-2910.
32. Katsuki A, Sumida Y, Murashima S, et al. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998;83:859-862.
33. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998;83:1818-1820.
34. Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-3456.
35. Shamir R, Shehadeh N, Rosenblat M, et al. Oral insulin supplementation attenuates atherosclerosis progression in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003;23:104-110.
36. Kubota T, Kubota N, Moroi M, et al. Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation 2003;107:3073-3080.
37. Dhindsa S, Tripathy D, Mohanty P, et al. Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factor-kappaB in mononuclear cells. Metabolism 2004;53: 330-334.
38. Aljada A, Mohanty P, Ghanim H, et al. Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. Am J Clin Nutr 2004;79:682-690.
39. Mohanty P, Ghanim H, Hamouda W, et al. Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. Am J Clin Nutr 2002;75:767-772.
40. Dandona P, Mohanty P, Ghanim H, et al. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab 2001;86:355-362.
41. Dandona P, Mohanty P, Hamouda W, et al. Inhibitory effect of a two day fast on reactive oxygen species (ROS) generation by leucocytes and plasma ortho-tyrosine and meta-tyrosine concentrations. J Clin Endocrinol Metab 2001;86:2899-2902.